BeiGene Signs a License and Supply Agreement with Bio-Thera for BAT1706 (biosimilar, bevacizumab) in China

 BeiGene Signs a License and Supply Agreement with Bio-Thera for BAT1706 (biosimilar, bevacizumab) in China

BeiGene Signs a License and Supply Agreement with Bio-Thera for BAT1706 (biosimilar, bevacizumab) in China

Shots:

  • Bio-Thera to receive $165M upfront, regulatory, and commercial milestones and is eligible to receive royalties on sales of the product. BeiGene to get the right to develop, manufacture, and commercialize BAT1706 in China, including Hong Kong, Macau, and Taiwan while Bio-Thera will retain rights for the therapy outside the licensed territory
  • The NMPA has recently accepted the BLA for BAT1706. The collaboration allows Bio-Thera to leverage BeiGene’s expertise to accelerate the development and commercialization of BAT1706 as a single agent regimen or as a component of combinational therapies
  • BAT1706 is a mAb, a biosimilar referencing Avastin which is a treatment option for solid tumor indications in China such as colorectal, lung, and liver cancers. Additionally, Bio-Thera plans to file for the approval of BAT1706 in the US and EU in the Q4’20

Click here ­to­ read full press release/ article | Ref: BeiGene  Image: JHL Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post